Company Overview and News


Add NVS
to your dashboard

Headline News

Tracking Tweedy Browne Portfolio - Q3 2017 Update

7h seekingalpha
The largest five individual stock positions are Cisco Systems, Berkshire Hathaway, Baidu Inc., Johnson & Johnson, and Alphabet, and they account for ~44% of the portfolio. (558-0)

Digital Pills That Talk to Your Doctor Are Here - WSJ

2017-11-19 wsj
U.S. authorities approved the world’s first digital drug, an antipsychotic pill that signals smartphones once it reaches the gut so doctors can track whether patients are taking their medication. (23-0)

Don't Let Home-Bias Investing Trip You Up

2017-11-18 seekingalpha
The total U.S. stock market has gained over 20% during the past year and is doing great. But for U.S. investors that are under-weighted to foreign stocks, it's not so great. Why? Because foreign stocks have convincingly outperformed U.S. equities, thereby causing a performance deficit. What's the problem? (338-1)

Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

2017-11-17 zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved a label expansion for its cancer drug Sutent (sunitinib malate). With this latest approval, Sutent’s label has been expanded as an adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (“RCC”) following surgery. This approval makes it the first and only adjuvant therapy for recurrent RCC, the most common type of kidney cancer. (94-0)

Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy

2017-11-17 investorplace
The current recommendation of Buy for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week. (6-0)

Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

2017-11-16 zacks
Shares of Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) have soared 236.4% year to date compared with the industry’s gain of 0.2%. Here we analyze the factors that led to the rally. (59-0)

Incyte (INCY) Initiates Essential Thrombocythemia Trial

2017-11-16 zacks
Incyte Corporation (INCY - Free Report) recently announced that the first patient has been treated in the RESET trial on ruxolitinib. (58-0)

Watch Out Gilead, Juno's Strategy Might Just Pay Off

2017-11-16 seekingalpha
Gilead acquired Kite in a blockbuster $11.9 B deal largely for its recently approved CD19 CAR-T product platform. (73-0)

Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

2017-11-15 zacks
Roche Holdings AG (RHHBY - Free Report) recently announced FDA clearance for the VENTANA MMR IHC Panel for immunohistochemistry (IHC) tests on colorectal cancer patients. (39-0)

Cramer Remix: My query for GE is 'Did you mislead us or yourselves?'

2017-11-14 cnbc
CNBC's Jim Cramer was looking for some reassurance when he and his "Squawk on the Street" colleagues Carl Quintanilla and David Faber interviewed the CEO of General Electric on Tuesday. (33-1)

Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In

2017-11-14 seekingalpha
GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17. (174-0)

US approves digital pill that tracks when patients take it - Channel NewsAsia

2017-11-14 channelnewsasia
REUTERS: U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology. (11-0)

UPDATE 1-U.S. approves digital pill that tracks when patients take it

2017-11-14 reuters
(Reuters) - U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology. (11-0)

UPDATE 1-New blood pressure range means half of Americans have hypertension

2017-11-14 reuters
(Reuters) - Tighter blood pressure guidelines from U.S. heart organizations mean millions more people need to make lifestyle changes, or start taking medication, in order to avoid cardiovascular problems. (21-0)

Novartis Looks To Challenge Regeneron's Turf: Who Will Win This War?

2017-11-13 seekingalpha
Novartis' data in Wet Age-related macular degeneration in two phase 3 trials showed to be superior over Regeneron's Eylea. (6-0)

CUSIP: 66987V109